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Abstract Transforming growth factors-L (TGFL1, 2 and 3) are
secreted in a complex with their propeptides (latency-associated
peptide 1 (LAP1), 2 and 3). TGFL signaling requires the
dissociation of LAP and TGFL, a process termed latent TGFL
activation. This process is a critical but incompletely understood
step in the regulation of TGFL function. In particular, the extent
to which activation mechanisms differ among the three TGFL
isoforms is relatively unexplored. We show here that KVL6 binds
and activates latent TGFL3. ß 2002 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Transforming growth factor-Ls (TGFL) are pleiotropic
growth factors that regulate cell di¡erentiation, cell division,
immune function and extracellular matrix production [1]. The
three mammalian TGFL isoforms (TGFL1, 2 and 3) are se-
creted as homodimeric proteins derived from the carboxy-ter-
mini of pro-TGFL dimers [2]. The remnant amino-terminal
dimer is named the latency-associated peptide (LAP) because
it remains non-covalently associated with TGFL and prevents
TGFL from binding TGFL receptors [3]. Activation of latent
TGFL requires the dissociation of LAP and TGFL. The latent
TGFL complex also includes a third protein, latent TGFL-
binding protein, which is linked by disul¢de bonds to LAP.
There are several candidate mechanisms for converting la-
tent TGFL to the active form [4], but our understanding of
this process is rudimentary. De¢ning the mechanisms by
which the various TGFL isoforms are activated would en-
hance our understanding of their speci¢c functions, but so
far most work has focused on TGFL1. The integrin KVL6 is
a recently identi¢ed activator of latent TGFL1 [5]. KVL6 binds
the RGD sequence in LAP1 and activates TGFL1, apparently
by causing a conformational change in LAP1 [5]. KVL6 is ex-
pressed exclusively in epithelial cells [6]. Mice lacking the L6
gene have in£ammation in the lung and skin, but do not
develop lung ¢brosis after exposure to bleomycin [5,7]. In
bleomycin-treated mice, the majority of TGFL-responsive
genes upregulated in control mice are not increased in L6-
null animals [8], suggesting that the protection of L6-null
mice is due to decreased TGFL activity.
Interestingly, LAP3 and LAP1 contain RGD sequences at
comparable locations, suggesting that TGFL3 activity is also
modulated by RGD-binding integrin(s). However, the se-
quence amino-terminal to the RGD di¡ers between LAP3
and LAP1, indicating that LAP1 and LAP3 might be ligands
for di¡erent integrins. Furthermore, the phenotype of L6 in-
tegrin null mice does not suggest a de¢cit of TGFL3 activity,
as there is no phenotypic overlap between L3=36 and
TGFL33=3 mice. (In contrast, L3=36 and TGFL1
3=3 mice
both develop in£ammation.) Nevertheless, we tested whether
LAP3 is a ligand for KVL6, and whether cells expressing KVL6
can activate latent TGFL3 since this knowledge is important
for understanding the biologic functions of both TGFL3 and
the L6 integrin.
2. Materials and methods
2.1. Cell culture, antibodies and reagents
HT-1080 cells were from the American Type Tissue Culture Col-
lection (Manassas, VA, USA), 293T cells were from David Ron
(NYU, New York, NY, USA), Vector-transfected and L6-integrin-
transfected 293 cells and SW480 cells were from Dean Sheppard
(UCSF, San Francisco, CA, USA) [9]. Vector-transfected and L6-in-
tegrin-transfected HT-1080 cells were generated as described in Wei-
nacker et al. [9]. TGFL13=3 liver ¢broblast cells from Anita Roberts
(NIH, Bethesda, MD, USA) were stably transfected with either
pCDNA3.1/Hygro(-) (TGFL13=3 cells) (Invitrogen; Carlsbad, CA,
USA) or pCDNA3.1/Hygro(-) containing the L6 cDNA (TGFL13=3/
L6 cells), and cloned by limiting dilution. Transfected mink lung ep-
ithelial cells (TMLC), which produce luciferase in response to TGFL,
were as described [10]. Mouse anti-KVL6 Mab 10D5 [11] was a gift of
Dean Sheppard. MAb 1D11 against active TGFL (all isoforms), anti-
TGFL1 (AF-101-NA), anti-TGFL2 (AB-112-NA) and anti-TGFL3
(AB-244-NA) were from RpD Systems (Minneapolis, MN, USA).
GM6001 was from Calbiochem. Other reagents were from Roche
Diagnostics Corporation (Indianapolis, IN, USA).
2.2. TGFL bioassays
To measure activation of endogenous TGFL3, we plated
TGFL13=3/L6 cells (8U104) or TGFL13=3 cells in 35-mm wells in
Dulbecco’s modi¢ed Eagle’s medium (DMEM)/0.1% bovine serum
albumin (BSA). After 16 h, the cells were trypsinized and replated
(1.5U104 per well) in 50 Wl of DMEM/0.1% BSA in 96-well plates.
TMLC (2.5U104), suspended in DMEM/0.1% BSA, were added to
the test cells in an equal volume. When appropriate, anti-TGFL1
(1 Wg/ml), anti-TGFL2 (10 Wg/ml), anti-TGFL3 (25 Wg/ml), 10D5 (20
Wg/ml), 1D11 (25 Wg/ml) or LAP (100 ng/ml) was added. Cell lysates
and total TGFL in conditioned media were assayed as described
[10,12]. All experiments were done in duplicate and repeated three
times with similar results. The data presented are the mean and the
standard error of the mean of a single experiment.
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To measure activation of TGFL after transfection of TGFL13=3
and TGFL13=3/L6 cells with various TGFL cDNAs, we plated cells
at 8U104 cells per 35-mm well in DMEM/fetal calf serum (FCS).
After 16 h, cells were transfected with 400 ng per well using Lipofect-
amine Plus (Life Technologies; Grand Island, NY, USA) per the
manufacturer’s protocol. After 16 h the cells were collected in 3 ml
of DMEM/10% FCS and replated in 96-well and 24-well plates (50 or
500 Wl per well, respectively). 96-well plates were used to measure
TGFL activation, and 24-well plates were used to measure total (la-
tent plus active) TGFL secretion, as follows. After 4 h, the media were
replaced with equal volumes of DMEM/0.1% BSA. TMLC (2U104
cells/well) were added to the 96-well plates (¢nal volume, 100 Wl per
well). Additional reagents were added as appropriate. Conditioned
media were generated in the 24-well plate mono-cultures. After 16^
24 h, TGFL activation was assessed by measuring luciferase activity in
the cell lysates from co-culture wells. Also after 16^24 h, total secreted
TGFL was measured by activating latent TGFL in media from mono-
culture wells (80‡C for 10 min). These samples were incubated with
TMLC overnight and luciferase activity measured [10]. Experiments
were repeated four times with similar results. Error bars show the
standard deviation of a single experiment.
2.3. Constructs
Mouse TGFL1 was obtained from G.J. Thorbecke (NYU, New
York, NY, USA). Human TGFL3 and human TGFL2 pRK5 expres-
sion vectors, from R. Derynck (UCSF, San Francisco, CA, USA),
were transferred into pCDNA3.1/Zeo(+) (Invitrogen; Carlsbad, CA,
USA). The cDNA sequences encoding LAP2 and LAP3 (without the
3P-TGFL sequence) were ampli¢ed by polymerase chain reaction using
the above cDNAs as templates, cloned into the pCDNA-Fc vector
(gift of Carl Blobel, Memorial Sloan-Kettering Cancer Center, New
York, NY, USA) and used for protein production and puri¢cation. A
Factor Xa protease site was inserted between the last amino acid of
LAP2 or LAP3 and the ¢rst amino acid of the Fc. To maximize LAP
expression, cysteine 27 was mutated to serine in the LAP3 sequence
and cysteine 24 was mutated to serine in the LAP2 sequence (GeneE-
ditor, Promega; Madison, WI, USA). Mutant versions of mTGFL1
(D246E), hTGFL3 (D263E), and hLAP3 C27S (D263E), in which the
RGD amino acid motif is changed to RGE, were made in the same
way. All cDNAs were sequenced prior to use.
2.4. Production and puri¢cation of LAPs
Recombinant LAP1 was produced using a baculovirus system [13].
A related procedure was used to purify LAP2, LAP3 and LAP3-RGE,
as follows. 293T cells were transfected with the appropriate LAP-Fc
construct using Lipofectamine Plus. Conditioned media were collected
72 h post-transfection. LAP-Fc fusion proteins were removed from
the media with protein-A agarose. LAPs were released by digestion
with Factor Xa, which was removed with soybean trypsin inhibitor
beads (Sigma). We con¢rmed protein purity by silver stain. Adhesion
assays were carried out as described [13]. Results are expressed as
absorbance or as a percentage where absorbance of serum-coated
and BSA-coated wells is 100 and 0%, respectively.
3. Results
3.1. TGFL3 LAP is a ligand for the integrin KVL6
We recently showed that the propeptide of TGFL1 (LAP1)
is a ligand for the integrins KVL1, KVL5, and KVL6 [13]. To
determine whether LAP3 is also a ligand for KVL6, we tested
the ability of KVL6-expressing cells to adhere to recombinant
LAP1, LAP3 and LAP3-RGE. Four di¡erent cell types stably
transfected with either vector alone or an expression vector
containing the L6 integrin cDNA were allowed to adhere to
protein-coated wells (Fig. 1). In L6-expressing cells, the L6
subunit pairs with endogenous KV subunit to produce the
KVL6 integrin. KVL6-expressing cells adhered equally well to
LAP1 and LAP3 (Fig. 1). Mock-transfected cells did not ad-
here to either LAP. Adhesion of KVL6-expressing cells to
LAP3 requires the RGD sequence as cells did not attach to
LAP3 lacking the RGD sequence (LAP3-RGE) (Fig. 1).
3.2. LAP1 and LAP3 support adhesion with similar e⁄cacy
The integrin KVL6 binds LAP1 present in the latent TGFL
complex and generates active TGFL1 [5], while another
LAP1-binding integrin, KVL1, does not activate TGFL1 [13].
In adhesion assays, cells expressing KVL6 can attach to LAP1
at coating concentrations that are 10-fold lower than the those
needed for attachment of KVL1-expressing cells [5,13]. We
compared the abilities of LAP1, LAP2 and LAP3 to promote
KVL6-mediated adhesion at various coating concentrations. As
shown in Fig. 2A, SW480/L6 cells adhered to LAP1 and LAP3
with similar dose-response. More than 50% of the cells ad-
hered to coating concentrations of less than 1 Wg/ml of pro-
tein, whereas in our prior work with KVL1, no adhesion oc-
curred at 1 Wg/ml [13]. The speci¢city of the adhesion shown
in Fig. 2A is demonstrated by the lack of adhesion to LAP3-
RGE or LAP2. Also, the anti-KVL6 antibody 10D5 blocked
cell adhesion to LAP3 (Fig. 2B).
3.3. TGFL1 knockout cells expressing KVL6 activate
endogenous TGFL3
We previously found that the most sensitive way to detect
KVL6-mediated activation of TGFL is to co-culture test cells
with TGFL-responsive reporter cells. To determine if KVL6
activates latent TGFL3, we sought a cell system in which
TGFL3 but not TGFL1 is expressed to eliminate a back-
Fig. 1. Cells transfected with the L6 integrin adhere to LAP1 and
LAP3 in an RGD-dependent fashion. Wells were coated with
LAP1, LAP3 or LAP3-RGE. HT-1080, SW480, TGFL13=3 and 293
cells, either stably transfected with a L6 integrin cDNA or a control
vector, were allowed to adhere to the coated wells.
Fig. 2. LAP1 and LAP3 support KVL6-dependent adhesion with
similar e⁄cacy. A: SW480 cells, stably transfected with a L6 integrin
cDNA, were allowed to adhere to wells coated with di¡erent con-
centrations of LAP1, LAP3, LAP3-RGE or LAP2. B: SW480/L6
cells, in the absence or presence of an KVL6-blocking antibody, were
allowed to adhere to wells coated with LAP3.
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ground signal of TGFL1 activation. We selected a TGFL1-
null ¢broblast line that secretes latent TGFL2 and TGFL3
(Fig. 3A, right) and stably transfected them with empty ex-
pression vector (TGFL13=3 cells) or vector encoding L6 integ-
rin (TGFL13=3/L6 cells). The TMLC reporter cells [10] secrete
only the TGFL2 isoform (Fig. 3A, left). Analysis of medium
from co-cultures of TGFL13=3 cells and TMLC revealed only
TGFL2 and TGFL3 (not shown), indicating that co-culture
conditions do not induce TGFL1 expression by TMLC.
Co-culture experiments indicated that TGFL13=3 cells ex-
pressing KVL6 activate endogenous latent TGFL3. TMLC cul-
tured with TGFL13=3/L6 cells had increased luciferase levels
(indicating the presence of active TGFL) compared to TMLC
cultured with TGFL13=3 cells (Fig. 3B). This increase did not
occur when either an KVL6-speci¢c blocking antibody or a
monoclonal antibody that inhibits all three TGFLs was
added. The addition of isoform-speci¢c antibody against
TGFL1 to the co-culture did not a¡ect the luciferase activity
induced by TGFL13=3/L6 cells (Fig. 3B), although this anti-
body blocks activation of TGFL1 by other L6-expressing cells
[5]. These results suggest that the TGFL13=3/L6 ¢broblasts
activate a TGFL isoform other than TGFL1. Thus, these ex-
periments strongly imply, but do not directly demonstrate,
that KVL6 activates latent TGFL3.
3.4. The integrin KVL6 activates transfected latent TGFL3
To demonstrate conclusively that TGFL3 is activated by
KVL6, we modi¢ed our assay in order to test speci¢c TGFL
isoforms and mutants thereof. We transfected TGFL13=3 cells
or TGFL13=3/L6 cells with an expression vector (empty or
containing TGFL1, TGFL3, TGFL1-RGE, TGFL3-RGE, or
TGFL2 cDNAs) and cultured these cells with TGFL reporter
cells (Fig. 4A). When KVL6-expressing cells were transfected
with TGFL1 or TGFL3 cDNA, active TGFL was generated as
indicated by an increase in luciferase activity. No active TGFL
was detected when non-KVL6-expressing cells were similarly
transfected. No increase of luciferase activity above the L6-
dependent activation of endogenous TGFL was seen when the
vector control, TGFL1-RGE, TGFL3-RGE or the TGFL2
cDNAs were used for transfection (Fig. 4A). Therefore,
TGFL1 and TGFL3 activation by KVL6 require the RGD se-
quence in LAP. Addition of protease inhibitors (aprotinin,
leupeptin, and the matrix metalloproteinase (MMP) inhibitor
GM6001) to the cultures did not decrease KVL6-mediated ac-
tivation (data not shown); these results agree with previous
studies of KVL6-mediated activation of TGFL1 [5].
To con¢rm that transfection e⁄ciencies were similar, we
measured total TGFL levels in conditioned media from the
Fig. 3. TGFL13=3 cells that express the integrin KVL6 activate a la-
tent TGFL isoform other than TGFL1. A: Serum-free media were
conditioned by TGFL reporter cells (TMLC) or TGFL13=3 cells.
Media were collected, heated to 80‡C for 10 min to activate latent
TGFL, and incubated overnight with TGFL reporter cells (TMLC).
Antibodies were added to inhibit the activity of speci¢c TGFL iso-
forms. Luciferase activity indicates the amount of active TGFL in
the sample. B: TGFL13=3 cells or TGFL13=3/L6 cells were co-cul-
tured for 16^20 h with reporter cells in the presence of various anti-
bodies. Luciferase activity indicates the amount of TGFL activated
in the culture.
Fig. 4. Cells expressing the integrin KVL6 activate latent TGFL3 in
an RGD-dependent manner. A: TGFL13=3 cells or TGFL13=3/L6
cells were transfected with an expression vector (no insert, TGFL,
TGFL3, TGFL1-RGE, TGFL3-RGE or TGFL2). Transfected cells
were co-cultured with TGFL reporter cells (see Section 2). B: The
relative amounts of total TGFL (active and latent) secreted by the
transfected cells were determined as in Fig. 3A. C: TGFL13=3 cells
or TGFL13=3/L6 cells were transfected with an expression vector
(no insert, TGFL1 or TGFL3), then co-cultured with TGFL reporter
cells. Anti-KVL6 or anti-TGFL1 were added as indicated.
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various TGFL-transfected cells (Fig. 4B). TGFL activity pro-
duced by TGFL13=3/L6 cells transfected with TGFL1 or
TGFL3 cDNA is prevented by the addition of an antibody
against KVL6 (Fig. 4C). Also, a TGFL1-speci¢c antibody pre-
vented the induction of luciferase activity observed when
TGFL13=3/L6 cells are transfected with TGFL1 but not
when transfected with TGFL3 (Fig. 4C).
4. Discussion
Activation of latent TGFL is a key regulatory step in TGFL
action. The extent to which activation mechanisms vary
among the three TGFL isoforms is not known, but signi¢cant
di¡erences appear to be possible because of sequence di¡er-
ences among the LAPs. For instance, LAP1 and LAP3, but
not LAP2, contain the integrin recognition sequence RGD,
suggesting that TGFL1 and TGFL3 may be regulated by
RGD-binding integrins. TGFL1 can be activated by KVL6
[5] and KVL8 (S. Nishimura, personal communication). In
contrast, cells expressing KVL1 and K5L1 can bind LAP1 but
do not activate TGFL, and cells transfected to express KVL3,
KIIbL3, or K8L1 do not activate endogenous TGFL (unpub-
lished data). To investigate the e¡ect of integrins on TGFL3
function, we tested whether LAP3 is a ligand for KVL6 and
whether TGFL3 is activated by KVL6. We identi¢ed LAP3 as a
ligand for the integrin KVL6 and demonstrated that KVL6 can
activate latent TGFL3 but not TGFL2.
LAP1 is clearly a physiologic ligand for KVL6 and appears
to promote adhesion in vitro more e¡ectively than do other
KVL6 ligands [14]. Our result that LAP1 and LAP3 are equally
e¡ective ligands for KVL6 suggests that LAP3 is also a phys-
iologic ligand.
Little is known about TGFL3 activation. MMP-2, -3 and -9
can activate all three isoforms of TGFL [15], and to our
knowledge this is the only prior report of TGFL3 activation.
Thrombospondin-1 (TSP1) activates TGFL1 and TGFL2, and
is predicted to activate TGFL3, but experiments with TGFL3
have not been published [16]. Plasmin is perhaps the most
studied TGFL activator, but no published evidence addresses
the ability of plasmin to activate TGFL2 or TGFL3.
TGFL1-null mice die of in£ammation beginning around
3 weeks of age [17]. The only reported defects in TGFL3-null
mice are cleft palate and abnormal pulmonary development
[18]. Presumably, TGFL3 activity during palatal fusion and
lung morphogenesis requires a TGFL3 activator. Because the
phenotypes of mice de¢cient for L6 integrin, TSP1, plasmino-
gen, or MMP-2, -3, -9 do not show these defects, none of
them is likely to be a unique TGFL3 activator in palatal
fusion or lung morphogenesis. Thus, these processes involve
redundant latent TGFL3 activators or an undiscovered unique
activator.
Undoubtedly, TGFL3 plays roles not revealed by TGFL3-
null mice. One such role might be to regulate in£ammation, as
TGFL1 does. Because TGFL3-null animals die perinatally, it
is not known if these mice would develop postnatal in£am-
mation. L6-null mice have lung and skin in£ammation, and
are resistant to bleomycin-induced pulmonary ¢brosis [7].
Based upon the signi¢cant expression of TGFL3 in the skin
and lung and the nearly identical in vitro functions of TGFL1
and TGFL3, it is possible that the phenotype of L3=36 animals
is due to a combined lack of TGFL1 and TGFL3 activities. It
will be interesting to examine other epithelial processes where
TGFL3 is involved. For instance, TGFL3 in£uences spermato-
genesis in the epididymis [19] and mammary gland involution
in the breast [20]. In both organs, TGFL3 and the L6-integrin
are expressed in the same cell types [6].
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